Towards the pharmacotherapy of hairy cell leukaemia

Bibliography

• BOURONCLE BA, WISEMAN BK, DOAN CA: Leukemic reticuloendotheliosis. Blood (1958) 13(7):609–630.
   PubMed Web of Science ®Google Scholar
• QUESADA JR, REUBEN J, MANNING JT, HERSH EM, GUTTERMAN JU: Alpha interferon for induction of remission in hairy-cell Leukemia. N Engl. J. Med. (1984) 310(1):15–18.
   PubMed Web of Science ®Google Scholar
• ••This is the first study describing the efficacy of IFN-a in HCL.
   Google Scholar
• ZAKARIJA A, PETERSON LC, TALLMAN MS: Splenectomy and treatments of historical interest. Best Piaci Res. Clin. Haematol (2003) 16(1):57–68.
   PubMed Web of Science ®Google Scholar
• MINTZ U, GOLOMB HM: Splenectomy as initial therapy in twenty-six patients with leukemic reticuloendotheliosis (hairy cell leukemia). Cancer Res. (1979) 39(7 Pt 1):2366–2370.
   Google Scholar
• •One of the first reports on the effects of splenectomy in HCL.
   Google Scholar
• JANSEN J, HERMANSJ, REMMEJ, DEN OTTOLANDER GJ, CARDOZO PL: Hairy cell leukaemia. Clinical features and effect of splenectomy. Scand. Haematol (1978) 21(1):60–71.
   PubMedGoogle Scholar
• GOLOMB HM, CATOVSKY D, GOLDE DW: Hairy cell leukemia: a five-year update on seventy-one patients. Ann. Intern. Med. (1983) 99(4):485–486.
   PubMed Web of Science ®Google Scholar
• JANSEN J, HERMANS J: Clinical staging system for hairy-cell Leukemia. Blood (1982) 60(3):571–577.
   PubMed Web of Science ®Google Scholar
• GOLOMB HM, VARDIMAN JW: Response to splenectomy in 65 patients with hairy cell leukemia: an evaluation of spleen weight and bone marrow involvement. Blood (1983) 61(2):349–352.
   PubMed Web of Science ®Google Scholar
• •This is the first study demonstrating the importance of the hairy cell index for disease prognosis.
   Google Scholar
• CASTRO-MALASPINA H, NAJEAN Y, FLANDRIN G: Erythrokinetic studies in hairy-cell leukaemia. Br. J. Haematol (1979) 42(2):189–197.
   PubMed Web of Science ®Google Scholar
• SMALLEY RV, CONNORS J, TUTTLE RL, ANDERSON S, ROBINSON W, WHISNANT JK: Splenectomy versus alpha interferon: a randomized study in patients with previously untreated hairy cell Leukemia. Am. J. Hematol (1992) 41(1):13–18.
   PubMed Web of Science ®Google Scholar
• NG JP, HOGG RB, CUMMING RL, MCCALLION J, CATOVSKY D: Primary splenic hairy cell leukaemia: a case report and review of the literature. Ear: J. Haematol (1987) 39(4):349–352.
   PubMed Web of Science ®Google Scholar
• AHMED S, RAT KR: Interferon in the treatment of hairy-cell Leukemia. Best Piaci Res. Gin. Haematol (2003) 16(1):69–81.
   PubMed Web of Science ®Google Scholar
• VEDANTHAM S, GAMLIEL H, GOLOMB HM: Mechanism of interferon action in hairy cell leukemia: a model of effective cancer biotherapy. Cancer Res. (1992) 52(5):1056–1066.
   PubMed Web of Science ®Google Scholar
• PLATANIAS LC, PFEFFER LM, BARTON KP, VARDIMAN JW, GOLOMB HM, COLAMONICI OR: Expression of the IFN alpha receptor in hairy cell leukaemia. Br.j Haematol (1992) 82(3):541–546.
   PubMed Web of Science ®Google Scholar
• BAKER PK, PETTITT AR, SLUPSKY JR et al.: Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion. Blood (2002) 100(2):647–653.
   PubMed Web of Science ®Google Scholar
• SMITH JW, LONGO DL, URBA WJ et al.: Prolonged, continuous treatment of hairy cell leukemia patients with recombinant interferon-alpha 2a. Blood (1991) 78(7):1664–1671.
   PubMed Web of Science ®Google Scholar
• RAT KR, DAVEY F, PETERSON B et al: Recombinant alpha-2b-interferon in therapy of previously untreated hairy cell leukemia: long-term follow-up results of study by Cancer and Leukemia Group B. Leukemia (1995) 9(7):1116–1120.
   PubMed Web of Science ®Google Scholar
• GOLOMB HM, FEFER A, GOLDE DW et al.: Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b. Semin. Omni (1988) 15(5 Suppl. 5):7–9.
   Google Scholar
• FEDERICO M, FRASSOLDATI A, LAMPARELLI T et al.: Long-term results of alpha interferon as initial therapy and splenectomy as consolidation therapy in patients with hairy cell Leukemia. Final report from the Italian Cooperative Group for HCL. Ann. Omni (1994) 5(8):725–731.
   Google Scholar
• BARDAWIL RG, GROVES C, RATAIN MJ, GOLOMB HM, VARDIMAN JW: Changes in peripheral blood and bone marrow specimens following therapy with recombinant alpha 2 interferon for hairy cell Leukemia. Am. J. Pathol (1986) 85(2):194–201.
   Web of Science ®Google Scholar
• RATAIN MJ, GOLOMB HM, VARDIMAN JW et al.: Relapse after interferon alfa-26 therapy for hairy-cell leukemia: analysis of prognostic variables. Oncol (1988) 6(11):1714–1721.
   Google Scholar
• FRASSOLDATI A, LAMPARELLI T, FEDERICO M et al: Hairy cell leukemia: a clinical review based on 725 cases of the Italian Cooperative Group (ICGHCL). Italian Cooperative Group for Hairy Cell Leukemia. Leak. Lymphoma. (1994) 13(3-4):307–316.
   Web of Science ®Google Scholar
• ZINZANI PL, LAURIA F, RASPADORI D et al.: Results in hairy-cell leukemia patients treated with alpha-interferon: predictive prognostic factors. Ear: Haematol (1992) 49(3):133–137.
   PubMed Web of Science ®Google Scholar
• •Describes the role of IFN-a maintenance in HCL.
   Google Scholar
• TROUSSARD X, FLANDRIN G: Hairy cell Leukemia. An update on a cohort of 93 patients treated in a single institution. Effects of interferon in patients relapsing after splenectomy and in patients with or without maintenance treatment. Leak. Lymphoma. (1994) 14\(Suppl. 1):99–105.
   Google Scholar
• GREVER M, KOPECKY K, FOUCAR MK et al.: Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an inteigioup study. I Clin. Oncol (1995) 13(4):974–982.
   PubMed Web of Science ®Google Scholar
• ••Compares the effects of pentostatin andIFN-a in HCL.
   Google Scholar
• HABERMANN TM, ANDERSEN JW, CASSILETH PA, BENNETT JM, OKEN MM: Sequential administration of recombinant interferon alpha and deoxycoformycin in the treatment of hairy cell leukaemia. Br. Haematol (1992) 80(4):466–471.
   PubMed Web of Science ®Google Scholar
• SPIERS AS, PAREKH SJ, BISHOP MB: Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin). Clin. Omni (1984) 2(12):1336–1342.
   PubMed Web of Science ®Google Scholar
• •This is the first study demonstrating the efficacy of pentostatin in HCL.
   Google Scholar
• PIRO LD, CARRERA CJ, CARSON DA, BEUTLER E: Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine. N Engl. I Med. (1990) 322(16):1117–1121.
   PubMed Web of Science ®Google Scholar
• •This is the first study demonstrating the efficacy of dadribin in HCL.
   Google Scholar
• KANTARJIAN HM, SCHACHNER J, KEATING MJ: Fludarabine therapy in hairy cell Leukemia. Cancer (1991) 67(5):1291–1293.
   PubMed Web of Science ®Google Scholar
• SAVEN A, PIRO L: Newer purine analogues for the treatment of hairy-cell Leukemia. N Engl. I Med. (1994) 330(10):691–697.
   PubMed Web of Science ®Google Scholar
• SPIERS AS, MOORE D, CASSILETH PA et al.: Remissions in hairy-cell leukemia with pentostatin (2'-deoxycoformycin). N Engl. I Med. (1987) 316(14):825–830.
   PubMed Web of Science ®Google Scholar
• KRAUT EH, GREVER MR, BOURONCLE BA: Long-term follow-up of patients with hairy cell leukemia after treatment with 2'-deoxycoformycin. Blood (1994) 84(12):4061–4063.
   PubMed Web of Science ®Google Scholar
• DEARDEN CE, MATUTES E, HILDITCH BL, SWANSBURY GJ, CATOVSKY D: Long-term follow-up of patients with hairy cell leukaemia after treatment with pentostatin or cladribine. Br. Haematol (1999) 106(2):515–519.
   PubMed Web of Science ®Google Scholar
• CATOVSKY D, MATUTES E, TALAVERA JG et al.: Long term results with neoxycoformycin in hairy cell Leukemia. Leak. Lymphoma. (1994) 14\(Suppl. 1):109–113.
   Google Scholar
• RIBEIRO P, BOUAFFIA F, PEAUD PY et al.: Long term outcome of patients with hairy cell leukemia treated with pentostatin. Cancer (1999) 85(1):65–71.
   PubMed Web of Science ®Google Scholar
• RAFEL M, CERVANTES F, BELTRAN JM et al.: Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer (2000) 88(2):352–357.
   PubMed Web of Science ®Google Scholar
• MALOISEL F, BENBOUBKER L, GARDEMBAS M et al: Long-term outcome with pentostatin treatment in hairy cell leukemia patients. A French retrospective study of 238 patients. Leukemia (2003) 17(1):45–51.
   Google Scholar
• DALAL BI, FREIER L, JOHNSTON JB, MERRY CC, ISRAELS LG: Peripheral blood and bone marrow changes following 2'-deoxycoformycin therapy in hairy cell Leukemia. Results of 200 weeks' follow-up. Cancer (1989) 63(1):14–22.
   Google Scholar
• KRAUT EH, NEFF JC, BOURONCLE BA, GOCHNOUR D, GREVER MR: Immunosuppressive effects of pentostatin. Clin. Omni (1990) 8(5):848–855.
   PubMed Web of Science ®Google Scholar
• JULIUSSON G, LILIEMARK J: Rapid recovery from cytopenia in hairy cell leukemia after treatment with 2-chloro-2'-deoxyadenosine (CdA): relation to opportunistic infections. Blood (1992) 79(4):888–894.
   PubMed Web of Science ®Google Scholar
• HOFFMAN MA, JANSON D, ROSE E, RAI KR: Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long- term follow-up.Oncol (1997)15(3):1138–1142.
   Google Scholar
• LAURIA F, RONDELLI D, ZINZANI PL et al.: Long-lasting complete remission in patients with hairy cell leukemia treated with 2-CdA: a 5-year survey. Leukemia (1997) 11(5):629–632.
   PubMed Web of Science ®Google Scholar
• CHESON BD, SORENSEN JM, VENA DA et al.: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the Group C protocol mechanism of the National Cancer Institute: a report of 979 patients. Clin. Oncol (1998) 16(9):3007–3015.
   Web of Science ®Google Scholar
• ••The first multi-centre study describing the efficacy of cladribine in a very large series of patients with HCL.
   Google Scholar
• HAKIMIAN D, TALLMAN MS, KILEY C, PETERSON L: Detection of minimal residual disease by immunostaining of bone marrow biopsies after 2-chlorodeoxyadenosine for hairy cell Leukemia. Blood (1993) 82(6):1798–1802.
   PubMed Web of Science ®Google Scholar
• TALLMAN MS, HAKIMIAN D, RADEMAKER AW et al.: Relapse of hairy cell leukemia after 2-chlorodeoxyadenosine: long-term follow-up of the Northwestern University experience. Blood (1996) 88(6):1954–1959.
   PubMed Web of Science ®Google Scholar
• SAVEN A, BURIAN C, KOZIOL JA, PIRO LD: Long-term follow-up of patients with hairy cell leukemia after cladribine treatment. Blood (1998) 92(6):1918–1926.
   PubMed Web of Science ®Google Scholar
• GOODMAN GR, BURIAN C, KOZIOL JA, SAVEN A: Extended follow-up of patients with hairy cell leukemia after treatment with cladribine. I Clin. Omni (2003) 21(5):891–896.
   Google Scholar
• LILIEMARK J, ALBERTIONI F, HASSAN M, JULIUSSON G: On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. Clin. Oncol (1992) 10(10):1514–1518.
   Web of Science ®Google Scholar
• •Compares different routes of administration for cladribine.
   Google Scholar
• VAN DEN NESTE E, DELANNOY A, VANDERCAM B et al.: Infectious complications after 2-chlorodeoxyadenosine therapy. Eur. Haematol (1996) 56(4):235–240.
   Google Scholar
• LAURIA F, BOCCHIA M, MAROTTA G, RASPADORI D, ZINZANI PL, RONDELLI D: Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia: a new treatment schedule effective and safer in preventing infectious complications. Blood (1997) 89(5):1838–1839.
   PubMed Web of Science ®Google Scholar
• •Describes the efficacy and toxicity of the weekly administration regimen of cladribine in HCL.
   Google Scholar
• SEYMOUR IF, KURZROCK R, FREIREICH EJ, ESTEY EH: 2-chlorodeoxyadenosine induces durable remissions and prolonged suppression of CD4+ lymphocyte counts in patients with 1532 hairy cell leukemia. Blood (1994) 83(10):2906–2911.
   PubMed Web of Science ®Google Scholar
• RASPADORI D, RONDELLI D, BIRTOLO S et al.: Long-lasting decrease of CD4+/CD45RA+ T cells in HCL patients after 2-chlorodeoxyadenosine (2-CdA) treatment. Leukemia (1999) 13(8):1254–1257.
   PubMed Web of Science ®Google Scholar
• •Describes the long-term immunological effects of dadribine in HCL.
   Google Scholar
• LAURIA F, RONDELLI D, RASPADORI D, BENFENATI D, TURA S: Rapid restoration of natural killer activity following treatment with 2-chlorodeoxyadenosine in 22 patients with hairy-cell leukemia. Ear: j Haematol (1994) 52(1):16–20.
   PubMed Web of Science ®Google Scholar
• MALONEY DG, LILES TM, CZERWINSKI DK et al: Phase I clinical trial using escalating single-dose infusion of chimeric anti-CD20 monoclonal antibody (IDEC-C2B8) in patients with recurrent B-cell lymphoma. Blood (1994) 84(8):2457–2466.
   PubMed Web of Science ®Google Scholar
• LAURIA F, LENOCI M, ANNINO L et al.: Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia. Haematologica (2001) 86001046–1050.
   Web of Science ®Google Scholar
• HAGBERG H, LUNDHOLM L: Ritwdmab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia. Br. Haematol (2001) 115(3):609–611.
   PubMed Web of Science ®Google Scholar
• NIEVA J, BETHEL K, SAVEN A: Phase IIstudy of ritwdmab in the treatment of cladribine-failed patients with hairy cell leukemia. Blood (2003) 102(3):810–813.
   PubMed Web of Science ®Google Scholar
• THOMAS DA, O'BRIEN S, BUESO-RAMOS C et al.: Ritwdmab in relapsed or refractory hairy cell leukemia. Blood (2003) 102(12):3906–3911.
   Google Scholar
• KREITMAN RJ, PASTAN I: Immunobiological treatments of hairy-cell leukaemia. Best Piaci Res. Clin. Haematol (2003) 16(1):117–133.
   PubMed Web of Science ®Google Scholar
• •An elegant review on the current immunological strategies for HCL.
   Google Scholar
• KREITMAN RJ, WILSON WH, BERGERON K et al.: Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N. Engl. J. Med. (2001) 345(4):241–247.
   PubMed Web of Science ®Google Scholar
• ROBBINS DH, MARGULIES I, STETLER-STEVENSON M, KREITMAN RJ: Hairy cell leukemia, a B-cell neoplasm that is particularly sensitive to the cytotoxic effect of anti-Tac(Fv)-PE38 (LMB-2). Clin. Cancer Res. (2000) 6(2):693–700.
   PubMed Web of Science ®Google Scholar
• KREITMAN RJ, WILSON WH, ROBBINS D et al.: Responses in refractory hairy cell leukemia to a recombinant immunotoxin. Blood (1999) 94(10):3340–3348.
   PubMed Web of Science ®Google Scholar
• CASSILETH PA, CHEUVART B, SPIERS AS et al.: Pentostatin induces durable remissions in hairy cell leukemia. Clin. Omni (1991) 9(2):243–246.
   PubMed Web of Science ®Google Scholar
• SEYMOUR JF, ESTEY EH, KEATING MJ, KURZROCK R: Response to interferon-alpha in patients with hairy cell leukemia relapsing after treatment with 2-chlorodeoxyadenosine. Leukemia (1995) 9(5):929–932.
   PubMed Web of Science ®Google Scholar
• JACOBS RH, VOKES EE, GOLOMB HM: Second malignancies in hairy cell leukemia. Cancer (1985) 56(6):1462–1467.
   PubMed Web of Science ®Google Scholar
• PAWSON R, A'HERN R, CATOVSKY D: Second malignancy in hairy cell leukaemia: no evidence of increased incidence after treatment with interferon alpha. Leak. Lymphoma (1996) 22(1-2):103–106.
   PubMed Web of Science ®Google Scholar
• AU WY, KLASA RJ, GALLAGHER R, LE N, GAS COYNE RD, CONNORS JM: Second malignancies in patients with hairy cell leukemia in british columbia: a 20-year experience. Blood(1998) 92(4):1160–1164.
   PubMed Web of Science ®Google Scholar
• KURZROCK R, STROM SS, ESTEY E et al.: Second cancer risk in hairy cell leukemia: analysis of 350 patients. Clin. Oncol (1997) 15(5):1803–1810.
   Web of Science ®Google Scholar
• FEDERICO M, ZINZANI PL, FRASSOLDATI A et al: Risk of second cancer in patients with hairy cell leukemia: long-term follow-up. Clin. Oncol (2002) 20(3):638–646.
   Web of Science ®Google Scholar
• QUESADA JR, HERSH EM, MANNING J et al: Treatment of hairy cell leukemia with recombinant alpha-interferon. Blood (1986) 68(2):493–497.
   PubMed Web of Science ®Google Scholar
• LAURIA F, FOA R, RASPADORI D et al: Treatment of hairy-cell leukaemia with alpha-interferon (alpha-IFN). Eur. .1 Cancer Clin. Omni (1988) 24(2):195–200.
   Google Scholar
• BERMAN E, HELLER G, KEMPIN S, GEE T, TRAN LL, CLARKSON B: Incidence of response and long-term follow-up in patients with hairy cell leukemia treated with recombinant interferon alfa-2a. Blood (1990) 75(4):839–845.
   PubMed Web of Science ®Google Scholar
• JOHNSTON JB, EISENHAUER E, WAINMAN N, CORBETT WE, ZAENTZ SD, DAENINCK PJ: Long-term outcome following treatment of hairy cell leukemia with pentostatin (Nipent): a National Cancer Institute of Canada study. Semin. Omni (2000) 27(2 Suppl. 5):32–36.
   Google Scholar
• FLINN IW, KOPECKY KJ, FOUCAR MK et al.: Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin. Blood (2000) 96(9):2981–2986.
   PubMed Web of Science ®Google Scholar
• ESTEY EH, KURZROCK R, KANTARJIAN HM et al.: Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine (2-CdA). Blood (1992) 79(4):882–887.
   PubMed Web of Science ®Google Scholar
• PIRO LD, ELLISON DJ, SAVEN A: The Scripps Clinic experience with 2-chlorodeoxyadenosine in the treatment of hairy cell leukemia. Leak. Lymphoma (1994) 14\(Suppl. 1):121–125.
   Google Scholar
• JULIUSSON G, HELDAL D, HIPPE E et al.: Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia. Clin. Oncol (1995) 13(4):989–995.
   Web of Science ®Google Scholar
• •Describes the effcacy of subcutaneous dadribine.
   Google Scholar
• JEHN U, BARTL R, DIETZFELBINGER H et al.: Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine. Ann. Hematol (1999) 78(3):139–144.
   PubMed Web of Science ®Google Scholar
• LAURIA F, BOCCHIA M, MAROTTA G, RASPADORI D, ZINZANI PL, RONDELLI D: Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications. Haematologica (1999) 84(1):22–25.
   PubMed Web of Science ®Google Scholar